Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

• Status: Completed
• Trial end date: 2018-02-09

Summary

This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).

• Phase: Phase 3

Details

• Lead Sponsor: Incyte Corporation
• Collaborator: Novartis Pharmaceuticals
• Treatments: Anagrelide; Hydroxyurea; Lenalidomide; Pipobroman; Pomalidomide